相关实验视频

Updated: Jul 6, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

在一般化肌痛性肌痛症中的efgartigimod:在国家参考中心的现实生活经验

Rita Frangiamore¹, Elena Rinaldi¹, Fiammetta Vanoli^1,2

¹Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.

European journal of neurology

|January 2, 2024

概括

在14个月的时间里,Efgartigimod (EFG) 治疗显著改善了一般化肌痛性硬化症 (gMG) 症状,并减少了住院治疗. 这种FcRn抑制剂在长期的gMG管理中证明了安全性和有效性.

科学领域:

神经学神经学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

新生儿Fc受体 (FcRn) 抑制是一种针对抗体介导疾病的新治疗方法.
一般化肌痛性肌痛症 (gMG) 是一种抗体介导的自身免疫性疾病.
埃夫加尔蒂吉莫德 (EFG) 是一种FcRn抑制剂,用于研究gMG治疗.

研究的目的:

评估efgartigimod (EFG) 在一般化骨髓灰质炎 (gMG) 患者的实际临床经验和疗效.
在14个月的随访期间评估EFG对疾病进程的安全性和影响.

主要方法:

一组19名患有gMG的患者根据GENERATIVE协议接受了EFG.
患者的抗体状况包括乙胆受体,肌肉特异性氨酸激酶和脂蛋白相关蛋白4抗体,以及三重阴性病例.
使用标准化临床尺度测量有效性:每日生活中的MG活动,MG复合和定量MG.

主要成果:

很大一部分患者需要多个治疗周期 (53%需要三次,26%需要四次,21%需要五次) 超过14个月.
每个治疗周期后都观察到有意义的临床改善.
EFG显著减少了住院治疗 (从42%降至0%),重症监护室入院 (从16%降至0%),以及像血交换或免疫球蛋白等救援疗法的需求 (从79%降至5%).

结论:

埃夫加尔蒂吉莫德 (EFG) 显示出良好的安全性,没有重大副作用或输液反应.
在14个月内,EFG显著改变了gMG患者的疾病进程.
以EFG为例的FcRn抑制是长期管理gMG的有价值的治疗策略.

关键词:

马斯克 (MuSK) 是一种乙胆受体的受体是什么在efgartigimod中使用.肌痛性骨髓灰质炎 (Myasthenia Gravis) 是一个严重的疾病.新生儿的Fc受体.

更多相关视频

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

相关概念视频

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Disorders of the Skeletal Muscle

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...